Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
The antibacterial spectrum of besifloxacin, a novel fluoroquinolone recently approved for treatment of ocular infections, was studied using 2,690 clinical isolates representing 40 species. Overall, besifloxacin was the most potent agent tested against gram-positive pathogens and anaerobes and was generally equivalent to comparator fluoroquinolones in activity against most gram-negative pathogens. Besifloxacin demonstrated potent, broad-spectrum activity, which was particularly notable against gram-positive and gram-negative isolates that were resistant to other fluoroquinolones and classes of antibacterial agents.
Haas
Wolfgang
W
Bausch & Lomb, Inc., 1400 N. Goodman St., Rochester, NY 14609, USA. wolfgang.haas@bausch.com
Pillar
Chris M
CM
Zurenko
Gary E
GE
Lee
Jacqueline C
JC
Brunner
Lynne S
LS
Morris
Timothy W
TW
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001381:Azepines / Q000494:pharmacology*; D001421:Bacteria, Anaerobic / Q000187:drug effects*; D024881:Drug Resistance, Bacterial / Q000187:drug effects; D024841:Fluoroquinolones / Q000494:pharmacology*; D006090:Gram-Negative Bacteria / Q000187:drug effects; D006094:Gram-Positive Bacteria / Q000187:drug effects; D008826:Microbial Sensitivity Tests
D000900:Anti-Bacterial Agents; D001381:Azepines; D024841:Fluoroquinolones; C522124:besifloxacin